<DOC>
	<DOCNO>NCT00767117</DOCNO>
	<brief_summary>The purpose study determine effect steady-state concentration LPV , co-administered low dose ritonavir , steady-state pharmacokinetics TMC125 determine effect steady-state concentration TMC125 steady-state pharmacokinetics LPV , co-administered low dose ritonavir .</brief_summary>
	<brief_title>TMC125-TiDP2-C197 : A Phase I Trial Investigate Pharmacokinetic Interaction Between Lopinavir/Ritonavir TMC125 Both Steady-state Healthy Volunteers .</brief_title>
	<detailed_description>This Phase I , open-label , randomize ( patient assign different treatment base chance ) , 2-period , 2-way cross-over interaction trial investigate pharmacokinetic interaction ( study bodily absorption , distribution , metabolism , excretion drug ) lopinavir/ritonavir ( LPV/rtv ) TMC125 , steady-state.The trial population consist 16 healthy volunteer . In 2 consecutive session , healthy volunteer receive Treatment A Treatment B , randomize sequence . In Treatment A , 200 mg TMC125 b.i.d.will administer 7 day ( Day 1 Day 7 ) additional morning dose Day 8 . In Treatment B , 400/100 mgLPV/rtv twice day administer 15 day ( Day 1 Day15 ) additional morning dose Day 16 , 200 mgTMC125 b.i.d . co-administered Day 9 Day 15 additional morning dose Day 16 . Subsequent session separate washout period least 2 week . Full pharmacokinetic profile TMC125 determine 12-hour dose interval morning intake Day 8 Treatment A Day 16 Treatment B . Full pharmacokinetic profile LPV ritonavir determine 12-hour dose interval morning intake Days 8 16 Treatment B . All treatment administer fed condition take within 10 minute meal . Safety tolerability evaluation record continuously . Treatment A = 200 mg TMC125 b.i.d . administer 7 day ( Day 1 Day 7 ) additional morning dose Day 8 . Treatment B = 400/100 mg LPV/rtv b.i.d . administer 15 day ( Day 1 Day 15 ) additional morning dose Day 16 , 200 mg TMC125 b.i.d . co-administered Day 9 Day 15 additional morning dose Day 16 .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Nonsmoking smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior selection Normal weight define Quetelet Index ( Body Mass Index [ BMI ] , weight kg divide square height meter ) 18.0 30.0 kg/m2 , extremes include Informed Consent Form ( ICF ) sign voluntarily first trialrelated activity Able comply protocol requirement Healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination , medical history , electrocardiogram ( ECG ) , vital sign , result blood biochemistry , hematology urinalysis carry screen . No positive HIV1 HIV2 test Screening No hepatitis A infection ( confirm hepatitis A antibody IgM ) , hepatitis B infection ( confirm hepatitis B surface antigen ) , hepatitis C infection ( confirm hepatitis C virus antibody ) study screen No currently active underlie gastrointestinal , cardiovascular , nervous system , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease No currently significant diarrhea , gastric stasis , constipation investigator 's opinion could influence drug absorption bioavailability No history significant skin disease , limited , rash eruption , drug allergy , food allergy , dermatitis , eczema , psoriasis , urticaria No previously demonstrate clinically significant allergy hypersensitivity excipients investigational medication administer trial No use concomitant medication , include overthecounter product dietary supplement . Overthecounter systemic medication must discontinue least 7 day prior first dose study medication prescribe medication product contain Hypericum perforatum must discontinue least 14 day first dose study medication , except paracetamol/acetaminophen ibuprofen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>TMC125-C197</keyword>
	<keyword>TMC125-TiDP2-C197</keyword>
	<keyword>HIV</keyword>
	<keyword>DDI</keyword>
	<keyword>Lopinavir</keyword>
	<keyword>Intelence</keyword>
	<keyword>Kaletra</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Etravirine</keyword>
	<keyword>Interaction</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Steady-state</keyword>
</DOC>